Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | STAT1 | P42224 | 1/20 | 1.00 |
| ▸ | CASP3 | P42574 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipriflavone SCHEMBL111472 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8635594 | 0.89 | ALDH2 (0.83) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL738941 | 0.88 | ALDH2 (0.80) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11557001 | 0.88 | ALDH1A1 (0.78) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1701110 | 0.87 | ALDH2 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28048765 | 0.87 | ALDH1A1 (0.77) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11012140 | 0.87 | ALDH2 (0.77) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2070406 | 0.86 | NPC1 (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL762092 | 0.85 | MAPT (1.00) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11012372 | 0.85 | MAPT (0.73) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119174754-A | Use of Ipriflavone in combating respiratory syncytial virus infection | 苏州大学 | 2024-12-24 | — | — | CN | claimed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| US-12594249-B2 | Soluble curcumin and its derivatives | THERMOLIFE INTERNATIONAL, LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-31 | — | — | US | disclosed |
| CN-119174754-B | Use of Ipriflavone in combating respiratory syncytial virus infection | 苏州大学 | 2025-09-26 | — | — | CN | disclosed |
| CN-119174754-B | Use of Ipriflavone in combating respiratory syncytial virus infection | 苏州大学 | 2025-09-26 | — | — | CN | disclosed |
| EP-4340868-B1 | SECRETED SPLICING VARIANT OF KLOTHO FOR TREATING BONE DISORDERS | UNIV AUTòNOMA DE BARCELONA (ES) | 2025-07-09 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2024250032-A9 | SOLUBLE CURCUMIN AND ITS DERIVATIVES | THERMOLIFE INTERNATIONAL, LLC (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2022243519-A1 | SECRETED SPLICING VARIANT OF KLOTHO FOR TREATING BONE DISORDERS | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2022-11-24 | — | — | WO | disclosed |
| US-11491123-B2 | Pharmaceutical compositions with antiflaviviral activity | HEALTH RESEARCH, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-4071473-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | Ascentawits Pharmaceuticals, Ltd. (CN) | 2022-10-12 | — | — | EP | disclosed |
| EP-4062772-A2 | ENCLOSING MATERIALS IN NATURAL TRANSPORT SYSTEMS | Incredible Foods, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-112386702-B | Compositions and methods for reducing drug tolerance in patients with hormone-dependent diseases | 中国科学院分子细胞科学卓越创新中心 | 2022-08-30 | — | — | CN | disclosed |
| CN-114931573-A | Application of ipriflavone in inhibiting activation of NLRP3 inflammatory corpuscle | 浙江中医药大学 | 2022-08-23 | — | — | CN | disclosed |
| WO-2022163852-A1 | COMPOSITION FOR INHIBITING EXPRESSION OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) AND/OR TMPRSS2 | 株式会社 バイオミメティクスシンパシーズ | 2022-08-04 | — | — | WO | disclosed |
| US-11400106-B2 | Methods for inhibiting microbe growth | MCMASTER UNIVERSITY (CA) | 2022-08-02 | — | — | US | disclosed |
| CN-114414608-A | Method for detecting SIRTs deacetylase activity based on one-dimensional HNCO nuclear magnetic resonance spectrum and application | 深圳大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022034664-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES | 株式会社ジェクスヴァル | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491123-B2 | Pharmaceutical compositions with antiflaviviral activity | ETFB, ETFA, TTN | ALDH1A1 3139/4885MAPT 861/4885SMN1; SMN2 331/4885 |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | GPR139, OPRL1, GRIN2C | ALDH1A1 1460/4885MAPT 413/4885SMN1; SMN2 1227/4885 |
| US-11400106-B2 | Methods for inhibiting microbe growth | MMP8, BPGM, CAPG | ALDH1A1 1494/4885MAPT 4695/4885SMN1; SMN2 2930/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ALDH1A1 2943/4885MAPT 330/4885SMN1; SMN2 831/4885 |
| US-12594249-B2 | Soluble curcumin and its derivatives | SLC2A8, SLC2A2, SLC2A1 | ALDH1A1 435/4885MAPT 299/4885SMN1; SMN2 2615/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | ALDH1A1 1685/4885MAPT 360/4885SMN1; SMN2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.